Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its LBP-ShC4 in androgenic alopecia (AGA). This marks a significant step forward in the development of this innovative live biotherapeutic product (LBP).

LBP-ShC4: A First-in-Class Therapy
LBP-ShC4 is a self-developed live biotherapeutic product (LBP) designed to treat androgenic alopecia. It stands out as the first product of its kind with no comparable therapy approved globally for this indication.-Fineline Info & Tech